Tamada K, Harada M, Abe K, Li T, Tada H, Onoe Y, Nomoto K
Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Cancer Immunol Immunother. 1998 May;46(3):128-36. doi: 10.1007/s002620050471.
In order to enhance the antitumor vaccination effect of dendritic cells (DC) pulsed with class I tumor peptide, we tried to utilize the local cytokine help of CD4+ T cells reactive to a streptococcal preparation OK432. DC were prepared from murine bone marrow cells by culture with both granulocyte/macrophage-colony-stimulating factor and interleukin(IL)-4. The peritumoral injections of OK432 induced OK432-reactive CD4+ T cells in the draining lymph nodes, and their in vitro production of interferon gamma was thus significantly enhanced by restimulation with OK432-pulsed DC. In addition, anti-P815 mastocytoma cytotoxic T lymphocytes were generated from the in vivo OK432-treated P815-draining lymph node cells only when the lymph node cells were restimulated in vitro with the DC pulsed with both P1A peptide and OK432. Moreover, the peritumoral injections of OK432 and the subsequent vaccination of the DC, pulsed with both OK432 and P1A peptide, significantly suppressed the growth of s.c. inoculated P815. Interestingly, a significant level of IL-12 was detected in the coculture supernatant of both OK432-pulsed DC and OK432-reactive CD4+ T cells. Collectively, our results suggest that the antitumor vaccination effect of DC pulsed with class I tumor peptide could thus be effectively augmented by locally utilizing the Th1-type cytokines from OK432-reactive CD4+ T cells.
为了增强用I类肿瘤肽脉冲处理的树突状细胞(DC)的抗肿瘤疫苗接种效果,我们试图利用对链球菌制剂OK432有反应的CD4 + T细胞的局部细胞因子辅助作用。通过用粒细胞/巨噬细胞集落刺激因子和白细胞介素(IL)-4培养从小鼠骨髓细胞制备DC。肿瘤周围注射OK432可在引流淋巴结中诱导产生对OK432有反应的CD4 + T细胞,因此用OK432脉冲处理的DC再次刺激可显著增强其体外干扰素γ的产生。此外,仅当淋巴结细胞在体外被用P1A肽和OK432脉冲处理的DC再次刺激时,才能从体内经OK432处理的P815引流淋巴结细胞中产生抗P815肥大细胞瘤细胞毒性T淋巴细胞。此外,肿瘤周围注射OK432以及随后用OK432和P1A肽脉冲处理的DC进行疫苗接种,可显著抑制皮下接种的P815的生长。有趣的是,在OK432脉冲处理的DC和对OK432有反应的CD4 + T细胞的共培养上清液中检测到显著水平的IL-12。总体而言,我们的结果表明,通过局部利用来自对OK432有反应的CD4 + T细胞的Th1型细胞因子,可以有效地增强用I类肿瘤肽脉冲处理的DC的抗肿瘤疫苗接种效果。